TOP HEADLINES

Featured Story

Otsuka, Horizon team up on early-stage development

Horizon Discovery, which makes its money providing development expertise to drugmakers, has signed a deal with Otsuka Pharmaceutical to apply its technology to some early-phase treatments.

Contractor ABL snags an immune-focused CRO

Maryland's ABL has struck a deal to buy a majority stake in Platine Pharma Services, a French contract R&D organization that specializes in substances that provoke an immune response.

Icon will teach Cambridge students how to market drugs

Global CRO Icon has deepened its longstanding relationship with Cambridge University, agreeing to lead a class on pricing and market access for new drugs.

TransCelerate taps Cognizant to get its Big Pharma backers on the same page

TransCelerate BioPharma, a nonprofit run by 19 of the world's largest drugmakers, formed two years ago to help Big Pharma share resources and stop wasting time and money on noncompetitive work. Now, the group is looking to create a novel platform to standardize how clinical trial sites communicate with sponsors, choosing contractor Cognizant to develop it.

SRI's in-house CRO inks a $49M deal with NIH

The CRO unit of nonprofit researcher SRI International has paired up with NIH's National Institute of Allergy and Infectious Diseases, signing a $49 million contract to handle preclinical work on potential treatments for HIV.

MORE NEWS

From Our Sister Sites

FierceBiotech

Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with Novartis worth up to $680 million.

FiercePharma

Johnson & Johnson's new blood cancer drug Imbruvica (ibrutinib) is on a roll. The FDA just armed the drug with a new indication in chronic lymphocytic leukemia, adding to a series of regulatory nods.